TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients

Sun Och Yoon, Young Tae Kim, Kyeong Cheon Jung, Yoon Kyung Jeon, Baek Hui Kim, Chul Woo Kim

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) have been identified in peripheral blood of cancer patients, and reproducible detection of CTCs has demonstrated the potential as useful diagnostic and prognostic tools in several cancers. Present study aimed to determine the clinical relevance of CTCs in surgically resected non-small cell lung cancer (NSCLC) patients. CTC status in presurgery and postsurgery peripheral blood samples from 79 surgically resected NSCLC patients was investigated using thyroid transcription factor-1 (TTF-1) and cytokeratin19 (CK19) mRNA markers by nested real-time RT (reverse transcription)-PCR assay. Detection of TTF-1 (+)CTCs was found to be specific to NSCLC patients. TTF-1 (+)CTCs were detected in 36.1% (22/61) of patients before surgery and in 37.5% (18/48) after surgery. For CK19 mRNA-expressing CTCs (CK19 (+)CTCs), the detection rate was 42.6% (26/61) before surgery, and 25.0% (12/48) after surgery. Cases with postsurgery TTF-1 (+) and/or CK19 (+)TCs was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.006) as compared to those without postsurgery CTCs. As an individual marker, postsurgery TTF-1 (+)CTCs-positive status was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.004) as compared to postsurgery TTF-1 (+)CTCs-negative status. Particularly, patients with postsurgery TTF-1 (+)CTCs, but not presurgery (Pre (-)Post (+) cases) showed marked shorter disease progression-free survival than other patients (P<0.001). On the other hand, a CK19 (+)CTC status individually did not show significant clinical relevance, and presurgery CK19 (+)CTC status did not either. Present study suggests that TTF-1 mRNA-expressing CTCs might be a useful surrogate predictor of disease progression before clinical manifestations are apparent, and that monitoring of TTF-1 (+)CTCs status after surgery may be useful for identifying high-risk patients among surgically resected NSCLC cases.

Original languageEnglish
Pages (from-to)209-216
Number of pages8
JournalLung Cancer
Volume71
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Circulating Neoplastic Cells
Non-Small Cell Lung Carcinoma
Messenger RNA
Disease-Free Survival
Disease Progression
thyroid nuclear factor 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Yoon, Sun Och ; Kim, Young Tae ; Jung, Kyeong Cheon ; Jeon, Yoon Kyung ; Kim, Baek Hui ; Kim, Chul Woo. / TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. In: Lung Cancer. 2011 ; Vol. 71, No. 2. pp. 209-216.
@article{09ada0181f37470f9d3bae7ce324adce,
title = "TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients",
abstract = "Circulating tumor cells (CTCs) have been identified in peripheral blood of cancer patients, and reproducible detection of CTCs has demonstrated the potential as useful diagnostic and prognostic tools in several cancers. Present study aimed to determine the clinical relevance of CTCs in surgically resected non-small cell lung cancer (NSCLC) patients. CTC status in presurgery and postsurgery peripheral blood samples from 79 surgically resected NSCLC patients was investigated using thyroid transcription factor-1 (TTF-1) and cytokeratin19 (CK19) mRNA markers by nested real-time RT (reverse transcription)-PCR assay. Detection of TTF-1 (+)CTCs was found to be specific to NSCLC patients. TTF-1 (+)CTCs were detected in 36.1{\%} (22/61) of patients before surgery and in 37.5{\%} (18/48) after surgery. For CK19 mRNA-expressing CTCs (CK19 (+)CTCs), the detection rate was 42.6{\%} (26/61) before surgery, and 25.0{\%} (12/48) after surgery. Cases with postsurgery TTF-1 (+) and/or CK19 (+)TCs was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.006) as compared to those without postsurgery CTCs. As an individual marker, postsurgery TTF-1 (+)CTCs-positive status was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.004) as compared to postsurgery TTF-1 (+)CTCs-negative status. Particularly, patients with postsurgery TTF-1 (+)CTCs, but not presurgery (Pre (-)Post (+) cases) showed marked shorter disease progression-free survival than other patients (P<0.001). On the other hand, a CK19 (+)CTC status individually did not show significant clinical relevance, and presurgery CK19 (+)CTC status did not either. Present study suggests that TTF-1 mRNA-expressing CTCs might be a useful surrogate predictor of disease progression before clinical manifestations are apparent, and that monitoring of TTF-1 (+)CTCs status after surgery may be useful for identifying high-risk patients among surgically resected NSCLC cases.",
author = "Yoon, {Sun Och} and Kim, {Young Tae} and Jung, {Kyeong Cheon} and Jeon, {Yoon Kyung} and Kim, {Baek Hui} and Kim, {Chul Woo}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2010.04.017",
language = "English",
volume = "71",
pages = "209--216",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. / Yoon, Sun Och; Kim, Young Tae; Jung, Kyeong Cheon; Jeon, Yoon Kyung; Kim, Baek Hui; Kim, Chul Woo.

In: Lung Cancer, Vol. 71, No. 2, 01.02.2011, p. 209-216.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients

AU - Yoon, Sun Och

AU - Kim, Young Tae

AU - Jung, Kyeong Cheon

AU - Jeon, Yoon Kyung

AU - Kim, Baek Hui

AU - Kim, Chul Woo

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Circulating tumor cells (CTCs) have been identified in peripheral blood of cancer patients, and reproducible detection of CTCs has demonstrated the potential as useful diagnostic and prognostic tools in several cancers. Present study aimed to determine the clinical relevance of CTCs in surgically resected non-small cell lung cancer (NSCLC) patients. CTC status in presurgery and postsurgery peripheral blood samples from 79 surgically resected NSCLC patients was investigated using thyroid transcription factor-1 (TTF-1) and cytokeratin19 (CK19) mRNA markers by nested real-time RT (reverse transcription)-PCR assay. Detection of TTF-1 (+)CTCs was found to be specific to NSCLC patients. TTF-1 (+)CTCs were detected in 36.1% (22/61) of patients before surgery and in 37.5% (18/48) after surgery. For CK19 mRNA-expressing CTCs (CK19 (+)CTCs), the detection rate was 42.6% (26/61) before surgery, and 25.0% (12/48) after surgery. Cases with postsurgery TTF-1 (+) and/or CK19 (+)TCs was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.006) as compared to those without postsurgery CTCs. As an individual marker, postsurgery TTF-1 (+)CTCs-positive status was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.004) as compared to postsurgery TTF-1 (+)CTCs-negative status. Particularly, patients with postsurgery TTF-1 (+)CTCs, but not presurgery (Pre (-)Post (+) cases) showed marked shorter disease progression-free survival than other patients (P<0.001). On the other hand, a CK19 (+)CTC status individually did not show significant clinical relevance, and presurgery CK19 (+)CTC status did not either. Present study suggests that TTF-1 mRNA-expressing CTCs might be a useful surrogate predictor of disease progression before clinical manifestations are apparent, and that monitoring of TTF-1 (+)CTCs status after surgery may be useful for identifying high-risk patients among surgically resected NSCLC cases.

AB - Circulating tumor cells (CTCs) have been identified in peripheral blood of cancer patients, and reproducible detection of CTCs has demonstrated the potential as useful diagnostic and prognostic tools in several cancers. Present study aimed to determine the clinical relevance of CTCs in surgically resected non-small cell lung cancer (NSCLC) patients. CTC status in presurgery and postsurgery peripheral blood samples from 79 surgically resected NSCLC patients was investigated using thyroid transcription factor-1 (TTF-1) and cytokeratin19 (CK19) mRNA markers by nested real-time RT (reverse transcription)-PCR assay. Detection of TTF-1 (+)CTCs was found to be specific to NSCLC patients. TTF-1 (+)CTCs were detected in 36.1% (22/61) of patients before surgery and in 37.5% (18/48) after surgery. For CK19 mRNA-expressing CTCs (CK19 (+)CTCs), the detection rate was 42.6% (26/61) before surgery, and 25.0% (12/48) after surgery. Cases with postsurgery TTF-1 (+) and/or CK19 (+)TCs was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.006) as compared to those without postsurgery CTCs. As an individual marker, postsurgery TTF-1 (+)CTCs-positive status was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.004) as compared to postsurgery TTF-1 (+)CTCs-negative status. Particularly, patients with postsurgery TTF-1 (+)CTCs, but not presurgery (Pre (-)Post (+) cases) showed marked shorter disease progression-free survival than other patients (P<0.001). On the other hand, a CK19 (+)CTC status individually did not show significant clinical relevance, and presurgery CK19 (+)CTC status did not either. Present study suggests that TTF-1 mRNA-expressing CTCs might be a useful surrogate predictor of disease progression before clinical manifestations are apparent, and that monitoring of TTF-1 (+)CTCs status after surgery may be useful for identifying high-risk patients among surgically resected NSCLC cases.

UR - http://www.scopus.com/inward/record.url?scp=78650942408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650942408&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.04.017

DO - 10.1016/j.lungcan.2010.04.017

M3 - Article

C2 - 20471712

AN - SCOPUS:78650942408

VL - 71

SP - 209

EP - 216

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -